Article

Nanoparticles that communicate in vivo to amplify tumour targeting.

Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.
Nature Material (Impact Factor: 36.43). 06/2011; 10(7):545-52. DOI: 10.1038/nmat3049
Source: PubMed

ABSTRACT Nanomedicines have enormous potential to improve the precision of cancer therapy, yet our ability to efficiently home these materials to regions of disease in vivo remains very limited. Inspired by the ability of communication to improve targeting in biological systems, such as inflammatory-cell recruitment to sites of disease, we construct systems where synthetic biological and nanotechnological components communicate to amplify disease targeting in vivo. These systems are composed of 'signalling' modules (nanoparticles or engineered proteins) that target tumours and then locally activate the coagulation cascade to broadcast tumour location to clot-targeted 'receiving' nanoparticles in circulation that carry a diagnostic or therapeutic cargo, thereby amplifying their delivery. We show that communicating nanoparticle systems can be composed of multiple types of signalling and receiving modules, can transmit information through multiple molecular pathways in coagulation, can operate autonomously and can target over 40 times higher doses of chemotherapeutics to tumours than non-communicating controls.

1 Follower
 · 
153 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are an abundance of nanoparticle technologies being developed for use as part of therapeutic strategies. This review focuses on a narrow class of metal nanoparticles that have therapeutic potential that is a consequence of elemental composition and size. The most widely known of these are gold nanoshells that have been developed over the last two decades for photothermal ablation in superficial cancers. The therapeutic effect is the outcome of the thickness and diameter of the gold shell that enables fine tuning of the plasmon resonance. When these metal nanoparticles are exposed to the relevant wavelength of light, their temperature rapidly increases. This in turn induces a localized photothermal ablation that kills the surrounding tumor tissue. Similarly, gold nanoparticles have been developed to enhance radiotherapy. The high-Z nature of gold dramatically increases the photoelectric cross-section. Thus, the photoelectric effects are significantly increased. The outcome of these interactions is enhanced tumor killing with lower doses of radiation, all while sparing tissue without gold nanoparticles. Silver nanoparticles have been used for their wound healing properties in addition to enhancing the tumor-killing effects of anticancer drugs. Finally, platinum nanoparticles are thought to serve as a reservoir for platinum ions that can induce DNA damage in cancer cells. The future is bright with the path to clinical trials is largely cleared for some of the less complex therapeutic metal nanoparticle systems.For further resources related to this article, please visit the WIREs website.Conflict of interest: The authors have declared no conflicts of interest for this article.
    Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 12/2014; DOI:10.1002/wnan.1322 · 4.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances have been made in cancer chemotherapy through the development of conjugates for anticancer drugs. Many drugs have problems of poor stability, water insolubility, low selectivity, high toxicity, and side effects. Most of the chitosan nanoparticles showed to be good drug carriers because of their biocompatibility, biodegradability, and it can be readily modified. The anticancer drug with chitosan nanoparticles displays efficient anticancer effects with a decrease in the adverse effects of the original drug due to the predominant distribution into the tumor site and a gradual release of free drug from the conjugate which enhances drug solubility, stability, and efficiency. In this review, we discuss wider applications of numerous modified chitosan nanoparticles against different tumors and also focusing on the administration of anticancer drugs through various routes. We propose the interaction between nanosized drug carrier and tumor tissue to understand the synergistic interplay. Finally, we elaborate merits of drug delivery system at the tumor site, with emphasizing future challenges in cancer chemotherapy.
    Applied Microbiology and Biotechnology 03/2015; 99(5):2055-64. DOI:10.1007/s00253-015-6384-9 · 3.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper summarizes recent research findings concerning centrioles, centriole duplication, cen-triole overduplication, supernumerary centrioles, centrosomes, and centrosome amplification. The paper then discusses the status of ongoing research on the use of nanoparticles for cancer treatment. The research findings show that a centriole produces an electromagnetic field apparently due to the longitudinal oscillation of its microtubules (MTs). A cluster of centrioles is therefore presumed to produce an enhanced electromagnetic field. Individual centrioles are immersed in a cloud of electron-dense material (proteins) which together with the centrioles is known as the centrosome. A cluster of centrioles thus produces a cluster of centrosomes—a hallmark of cancer cells. With enhanced electromagnetic fields, centrosome clusters provide an attraction for magnetically charged nanoparticles. These nanoparticles however are not attracted to normal cells which with only two (or at most four) centrioles, have a weaker magnetic field. The idea is simple: Magnetized and therapeutic nanoparticles are directed toward tumors and then attracted to the centrosome clusters of the tumor cells. Once inside the tumor cells, the nanoparticles can release their toxins.
    Advances in Bioscience and Biotechnology 03/2015; 6(3):172-181. DOI:10.4236/abb.2015.63017

Full-text (2 Sources)

Download
95 Downloads
Available from
Jun 10, 2014